Biognosys brings proteomic breakthroughs to mainstream users

Biognosys, a provider of targeted proteomics solutions, has announced the software platform mProphet for large-scale applications in industrial and academic research. The software was recently published in ‘Nature Methods’: With the new tool researchers can analyze complex proteomics data and generate statistically validated results.

Image Credit: Shutterstock/White_Fox

The advancement is mProphet, a software package created by scientists from the Institute of Molecular Systems Biology at ETH Zurich and Biognosys Ltd, a leading provider of proteomics solutions to biology research partners. The software offers automated, standardized analysis of data gathered in multiple reaction monitoring mass spectrometry (MRM), or Targeted Proteomics.

A prominent leader in proteomics, Dr. Ruedi Aebersold, shared, “The development of the mProphet software tool is highly significant for the emerging field of targeted proteomics because it will allow users to generate statistically validated data sets right from the outset.”  Historically, researchers struggled to objectively analyze expansive, complex proteomics data. “The mProphet tool will avoid this pitfall for targeted proteomics and make data generated in different laboratories directly comparable. This matches last year’s Human Proteome Organization (HUPO) conference where the development of MRM assays for the whole human proteome was announced.  Now we have everything in hand to broadly apply MRM proteomics”.

The publication further highlights the software’s ability to increase protein target sensitivity in MRM proteomics across a range of organisms.  “An ability that once only existed among a particular group of scientists is becoming broadly available for industrial, academic, and clinical organizations.  This technology will increasingly be used in drug discovery, diagnostics, gene expression, crop science, metabolic research – basically any field related to proteins in any living organism”, said Dr. Oliver Rinner, CSO at Biognosys AG.

The software is already being used by academic laboratories and Biognosys. More information can be found at www.mprophet.org.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Biognosys. (2020, October 01). Biognosys brings proteomic breakthroughs to mainstream users. News-Medical. Retrieved on April 17, 2024 from https://www.news-medical.net/news/20110325/Biognosys-brings-proteomic-breakthroughs-to-mainstream-users.aspx.

  • MLA

    Biognosys. "Biognosys brings proteomic breakthroughs to mainstream users". News-Medical. 17 April 2024. <https://www.news-medical.net/news/20110325/Biognosys-brings-proteomic-breakthroughs-to-mainstream-users.aspx>.

  • Chicago

    Biognosys. "Biognosys brings proteomic breakthroughs to mainstream users". News-Medical. https://www.news-medical.net/news/20110325/Biognosys-brings-proteomic-breakthroughs-to-mainstream-users.aspx. (accessed April 17, 2024).

  • Harvard

    Biognosys. 2020. Biognosys brings proteomic breakthroughs to mainstream users. News-Medical, viewed 17 April 2024, https://www.news-medical.net/news/20110325/Biognosys-brings-proteomic-breakthroughs-to-mainstream-users.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Boehringer Ingelheim and Biognosys join forces on applying quantitative proteomics tools in drug discovery